road expert dinner slew
drug approv recap busi week
convers zoeti focu long game
recent host seri meet clint lewi evp intern op
steve frank ir london part global healthcar confer one
best perform name healthcar vs
despit somewhat year anim health end-market livestock condit
neg affect spread african swine fever asf china
lewi emphas key factor allow outperform
histor set-up well continu deliv name divers portfolio
contribut innov new product well-align vet
custom specif key headwind cattle/dairi us asf
believ trough level although time recoveri remain uncertain
regard simparica trio abaxi diagnost suit lewi express enthusiasm
opportun differenti portfolio provid un-match
breadth offer custom remain cautiou quantifi specif
impact near-term financi overal remain bullish anim health space
see one best posit compani industri maintain
neutral rate see share fairli valu current level
expert dinner highlight complex size trio oppi
last week also held investor dinner dr fabian kausch former head
boehring ingelheim anim health expect convers domin
discuss current companion anim parasiticid landscap challeng
get triple-combo flea/tick/intern parasit drug approv us
gaug simparica trio opportun dr kausch agre trio
like major blockbust upon approv import rememb anim
drug tend much gradual ramp revenu human
counterpart ie even blockbust like nexgard apoquel took sever year reach
even peak sale peak revenu often achiev year
launch addit consider like price trio like premium
stand-alone parasiticid market today variat overlap incid
flea/tick heartworm us rel low complianc parasiticid use
pet owner could play meaning role determin eventu contribut trio
topic dr kausch see potenti valu elanco/bay
combin particularli cost synergi benefit gain exposur
otc/retail channel mirror concern near-term growth profil
ad uncertainti deal term futur invest area interest
anim health repeat emphasi nutrit health enzym probiot
altern therapeut diagnostics/devices/genet seen
nascent opportun expect play larger role come year
updat asf spread us cattl slew
 report comment
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
continu
asf continu spread se asia
weve written previous on-going african swine fever asf outbreak china
one biggest headlin anim health space frequent
cite major risk industri lot uncertainti impact
futur year current outbreak began august rapidli spread
across china well neighbor mongolia eastern russia highli
contagi lethal diseas mortal affect wild domest
pig recent month outbreak continu spread southeast asia
addit case report china widespread report vietnam
neighbor countri exhibit
exhibit china continu focu asf continu spread elsewher south-east asia case recent report south korea
sinc last updat viru detect south korea septemb
situat continu deterior vietnam outbreak provinc
pig cull approach countri total inventori given
rapid speed spread viru past year believ outbreak
unlik stop near-term believ much south-east asia
risk note vietnam global pig inventori myanmar philippin
south korea compris meaning portion global product
roughli unit state believ situat may continu
deterior near-term chart
chart vietnam myanmar philippin south korea repres meaning portion global pig suppli
rest world
republ korea
unit state america
us cattl market see continu pressur beef dairi
us feedlot major user number anim health therapeut
feedlot oper util ionophor use antimicrobi close
use parasiticid employ regular vaccin strategi variou
respiratori diseas feedlot placement overal level cattle-on-fe
import metric gaug health livestock therapeut market
analysi usda data chart show past month seen
extend period soft placement lighter cattl lighter cattl
requir longer time spent feedlot prior slaughter well greater amount
antibiot drug like get sick feedlot thu
see may/jun data-point increment neg ah livestock drug
manufactur addit dairi market remain soft leav us cautiou
recoveri us cattl
chart placement lighter cattl feedlot soft past month
pound
product approv launch
simparica trio approv eu expect launch
follow posit opinion committe medicin product veterinari
use juli european commiss approv simparica trio septemb
trio tripl combo monthli chewabl tablet shown
effect kill flea tick prevent heartworm lungworm treat roundworm
hookworm expect plan launch trio eu
current await approv us well australia brazil canada japan
rumensin gener approv combo use
last week huvepharma receiv fda approv combin use
approv us earli juli believ compani would
commerci product receiv combin approv feed addit
use part mixtur sever product follow-on approv receiv
earlier previous expect may indic faster commerci timelin
look forward elanco earn call updat rumensin expect
prior approv elanco supplier rumensin/monensin unit
state us sale repres nearli total compani revenu
antech goe idexx sdma market renaltech
last week antech part mar petcar announc launch renaltech ai-
driven predict diagnost tool allow user predict chronic kidney diseas ckd
cat around two year sign diseas actual visibl note
idexx sdma product wide use detect ckd well kidney diseas
state injuri cat well-posit especi diagnos
diseas mani month tradit ie creatinin test see renaltech
attempt go market although earli tell
success product also highlight renaltech analyt
algorithm predict risk ckd base exist marker bun creatinin urin
ph etc actual test new biomark
po base pro-forma post-deal close ev/ebitda estim
target multipl discount compani broader anim health peer group
roughli given uncertainti around deal specif expect equiti dilut
financ compon
downsid risk price object deal integration/anti-trust challeng
competit gener launch key product slower-than-expect ramp new
product launch increas regul antibiot use livestock macroeconom
condit currenc risk
share trade signific premium broader anim health peer
group histor level howev given mani posit secular product
tailwind compani current enjoy believ premium valuat justifi
po base ep estim roughli in-lin histor
trend observ high growth life scienc diagnost tool compani
downsid risk po lower spend vet servic event
econom slowdown slower-than-expect uptak new product ou expans
competit lower-than-expect margin expans weather disrupt currenc
po base ep estim discount compani
histor trade multipl peer group believ valuat warrant given
headwind face compani busi challeng dairi market
broadli choppi end-market condit heavi invest plan compani
come year limit oper leverag
upsid risk po faster uptak new product improv oper leverag
acquisit compani improv market condit accret downsid
risk addit regul weather pattern diseas outbreak product
po base ep estim back dcf
assum wacc termin growth rate roughli in-lin
current multipl albeit slightli higher recent valuat trend
believ justifi given upsid new product launch increment capit
deploy margin expans opportun defens natur
upsid risk continu ramp new product larger-than-expect contribut
futur launch acceler growth abaxi acquisit
downsid risk price object competit select market new product
launch competitor weaker demand anim health product regulatori issu
failur get approv key product pipelin macroeconom
condit currenc risk headwind relat regul antibiot use
michael ryskin herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
bofa merril lynch iscurr act joint advis tobay ag connect
propos sale anim health busi toelanco anim health inc
announc august
us life scienc diagnost tool anim health coverag cluster
